153,972 Shares in C4 Therapeutics, Inc. $CCCC Acquired by Headlands Technologies LLC

Headlands Technologies LLC bought a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 153,972 shares of the company’s stock, valued at approximately $719,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CCCC. Engineers Gate Manager LP boosted its position in shares of C4 Therapeutics by 49.9% during the fourth quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock valued at $47,000 after buying an additional 8,130 shares during the last quarter. SummitTX Capital L.P. purchased a new stake in shares of C4 Therapeutics during the 1st quarter valued at about $28,000. CTC Alternative Strategies Ltd. bought a new stake in shares of C4 Therapeutics in the first quarter worth approximately $28,000. Man Group plc raised its holdings in shares of C4 Therapeutics by 15.0% during the third quarter. Man Group plc now owns 90,278 shares of the company’s stock valued at $200,000 after purchasing an additional 11,791 shares during the last quarter. Finally, Zacks Investment Management bought a new position in C4 Therapeutics during the third quarter valued at approximately $29,000. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics Trading Up 4.3%

Shares of CCCC stock opened at $3.87 on Wednesday. C4 Therapeutics, Inc. has a 12 month low of $1.69 and a 12 month high of $5.17. The stock has a market cap of $476.13 million, a P/E ratio of -3.87 and a beta of 2.94. The company has a 50 day simple moving average of $3.95 and a two-hundred day simple moving average of $3.38.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. As a group, equities analysts forecast that C4 Therapeutics, Inc. will post -0.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.